Showing 6461-6470 of 8687 results for "".
- Probiotic for Oily and Acne-Prone Skin Gets US Patenthttps://practicaldermatology.com/news/Probiotic-Oily-Acne-Prone-Skin-Gets-US-Patent/2474976/A probiotic for managing oily, acne-prone skin was awarded US Patent No. 12,194,068, Codex Labs announced. In an independent clinical trial at Integrative Skin Solutions Research involving 18 male and female subjects with mild to moderate acne, the measured improvement after 8 weeks of Cod
- National Psoriasis Foundation Awards ZORYVE Seal of Recognitionhttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-zoryve-seal-of-recognition/2474950/The National Psoriasis Foundation (NPF) awarded its first Seal of Recognition to ZORYVE® (roflumilast) cream and foam 0.3%, according to a press release from the Foundation. The NPF Seal of Recognition, according to the org
- LEO Pharma Launches Study of Delgocitinib for PPPhttps://practicaldermatology.com/news/leo-pharma-launches-study-of-delgocitinib-for-ppp/2474972/LEO Pharma announced today the initiation of a phase 2a trial looking at the safety and efficacy of delgocitinib cream in adults with palmoplantar pustulosis (PPP). According to a news release from the manufacturer, the DELTA
- Analysis: PBoNT/A and ABoNT/A Show Fastest Onset in Glabellar Line Treatmenthttps://practicaldermatology.com/news/prabotulinum-toxin-a-demonstrates-sustained-efficacy-at-day-180/2474898/A newly published study reports the comparative effects of four botulinum toxin A (BoNT/A) formulations on glabellar strain, with observed differences in onset, longevity, and muscular strain patterns. Researchers publishing
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Reliefhttps://practicaldermatology.com/news/effisayil-2-spesolimab-associated-with-long-term-gpp-relief/2474835/Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. Re
- Analysis: Air Pollution Linked with Elevated Disease Activity in Bullous Pemphigoidhttps://practicaldermatology.com/news/analysis-air-pollution-linked-with-elevated-disease-activity-in-bullous-pemphigoid/2474733/New retrospective research indicates a relationship between ambient air pollution and increased disease activity in patients with bullous pemphigoid (BP), compared to those with pemphigus. Researchers analyzed 617 clinic visit
- Socioeconomic Disparities Tied to HS Diagnoseshttps://practicaldermatology.com/news/socioeconomic-disparities-tied-to-hs-diagnoses/2474703/Patients living in lower socioeconomic neighborhoods are more likely to be diagnosed with hidradenitis suppurativa (HS), according to a new cross-sectional analysis of data from the University of California San Francisco (UCSF) health system.
- Arcutis Announces Expert Statements on Genital Psoriasishttps://practicaldermatology.com/news/arcutis-announces-expert-statements-on-genital-psoriasis/2474665/Arcutis Biotherapeutics, Inc. has announced new consensus statements aimed at improving the diagnosis and management of genital psoriasis, according to a company press release. The 14 statements, developed by a multidisciplinary group of dermatology and immunology experts with the Genital
- Dermeleve to Modify Program for Sampleshttps://practicaldermatology.com/news/Dermeleve-Modify-Program-Samples/2474651/Dermeleve will transition away from its auto-ship model and self-serve request program for samples, but will still offer samples directly to patients and to clinicians who choose to hole wholesale inventory, the company said in an email to partners. “To ensure your patients can still ‘try